Compounds and uses to treat tauopathy
WO2026025073A1PCT designated stage Publication Date: 2026-01-29TAUGEN LLC
Patent Information
- Application Number
- PCT/US2025/039330
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-01-30
- Filing Date
- 2025-07-25
- Publication Date
- 2026-01-29
Smart Images
Figure IMGF000006_0001 
Figure IMGF000007_0001 
Figure IMGF000008_0001
Abstract
This invention provides compounds and uses to treat tauopathy and disorders related to tauopathies, including but not limited to traumatic brain injury (TBI), for example repetitive TBI (rTBI), as well as pharmaceutically acceptable salts and pharmaceutical compositions thereof. The invention also provides methods for the prevention, minimization or treatment of endoplasmic reticulum stress, including chronic traumatic encephalopathy (CTE) by administering an effective amount of a compound of this invention or a pharmaceutically acceptable salt, or a pharmaceutical composition thereof to a patient in need thereof.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Vanilloid receptor ligands and their use in treatments
US20090264424A1
Aminopyrimidine compounds and methods of use
US7858785B2
Potassium channel openers
WO2001009096A2
N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
WO2003006423A1
Compounds and therapeutic uses thereof
WO2011109441A1